TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9135404

Group type: EXPERIMENTAL
Intervention: Inhaled 100% oxygen
Number of subjects: 37

Group type: COMPARATOR
Intervention: Inhaled air (control)
Number of subjects: 37
Study: 8201695

Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin chemotherapy (3 courses of 90 mg/m² given for 3 consecutive days at monthly intervals)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin chemotherapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Postoperative cisplatin chemotherapy and Observation
Number of subjects: 77
Study: 3284752

Group type: EXPERIMENTAL
Intervention: Mianserin (30-80 mg daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trazodone (150-400 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1297641

Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen (750-mg tablet) after fasting
Number of subjects: 12

Group type: COMPARATOR
Intervention: Controlled-release naproxen (750-mg tablet) after a standard meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen with food
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen fasting vs postprandial
Number of subjects: 12
Study: 593995

Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (normal smoking)
Number of subjects: 8
Study: 31252661

Group type: EXPERIMENTAL
Intervention: Alpha-s1 casein hydrolysate (ACH; Lactium®)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29279300

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study: 26597952

Group type: EXPERIMENTAL
Intervention: Edaravone (30 mg twice per day for 14 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (100 ml saline twice per day for 14 days)
Number of subjects: 65
Study: 25088832

Group type: EXPERIMENTAL
Intervention: Ultrasound histogram features for acute toxicity assessment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ultrasound histogram features for late toxicity assessment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 34
Study: 23495538

Group type: EXPERIMENTAL
Intervention: Gratitude condition
Number of subjects: 90

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hassle condition
Number of subjects: 90
Study: 18836845

Group type: EXPERIMENTAL
Intervention: Serum procalcitonin (PCT) with a cut-off value of 0.85 ng/ml
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Erythrocyte sedimentation rate (ESR)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Leukocyte count
Number of subjects: 57

Group type: COMPARATOR
Intervention: Comparison of PCT, ESR, and CRP
Number of subjects: 57
Study: 17164307

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (10 g testosterone gel daily for 24 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (daily for 24 weeks)
Number of subjects: 88
Study: 15976211

Group type: EXPERIMENTAL
Intervention: Preoperative field block plus rofecoxib, 50 mg preoperatively and for 5 days postoperatively (PLR)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Preoperative bupivacaine field block and perioperative placebo (PL)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care (CONT)
Number of subjects: 75
Study: 11999936

Group type: EXPERIMENTAL
Intervention: Powered toothbrush fitted with a modified orthodontic brush head (Braun Oral-B Plaque Remover 3D)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Manual toothbrush (Reach Compact Medium)
Number of subjects: 63
Study: 10210035

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB, 2‐4 g daily)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Sodium Valproate (VPA, 1‐2 g daily)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Sodium Valproate (VPA)
Number of subjects: 215
Study: 7790126

Group type: EXPERIMENTAL
Intervention: Self-reported alcohol use
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Self-reported tobacco use
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Self-reported illicit drug use
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Sexual risk-taking
Number of subjects: 1387
Study: 2219505

Group type: EXPERIMENTAL
Intervention: Hemoccult‐II test (H‐II) positive
Number of subjects: 308

Group type: COMPARATOR
Intervention: Hemoccult‐II test (H‐II) negative
Number of subjects: 308
Study: 581782

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tolamolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30765389

Group type: EXPERIMENTAL
Intervention: Pazopanib with concomitant GAS therapy
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Pazopanib without concomitant GAS therapy
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 333
Study: 28604926

Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine) 274 mg administered orally at bedtime for up to 25 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine) 274 mg
Number of subjects: 126
Study: 25353053

Group type: EXPERIMENTAL
Intervention: Tadalafil (TAD) 5mg coadministered with finasteride (FIN) 5mg once daily for 26 weeks
Number of subjects: 695

Group type: COMPARATOR
Intervention: Placebo (PBO) coadministered with finasteride (FIN) 5mg once daily for 26 weeks
Number of subjects: 695
Study: 23339180

Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2 mA cathodal tDCS
Number of subjects: 14

Group type: COMPARATOR
Intervention: 1 mA cathodal tDCS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 14
Study: 20593411

Group type: EXPERIMENTAL
Intervention: AMG 785 (0.1, 0.3, 1, 3, 5, or 10 mg/kg subcutaneously or 1 or 5 mg/kg intravenously)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AMG 785
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 19299508

Group type: EXPERIMENTAL
Intervention: Leg-press exercise only (LP group)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Hip adduction combined with leg-press exercise (LPHA group)
Number of subjects: 89

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 89
Study: 17483532

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 20 mg subcutaneously daily
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 15470215

Group type: EXPERIMENTAL
Intervention: Lamivudine (100 mg per day)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 651
Study: 12468786

Group type: EXPERIMENTAL
Intervention: Isolated wrist extension movements in patients with partial recovery
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 11
Study: 9583069

Group type: EXPERIMENTAL
Intervention: Laparoscopic retroperitoneal uterine suspension (n = 32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Diagnostic laparoscopy (n = 30)
Number of subjects: 62
Study: 7637176

Group type: EXPERIMENTAL
Intervention: 1.25 mg of droperidol added to buprenorphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 mg of droperidol added to buprenorphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mg of droperidol added to buprenorphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Only buprenorphine
Number of subjects: 60
Study: 2759074

Group type: EXPERIMENTAL
Intervention: Isotonic glucose-electrolyte solution
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no drink)
Number of subjects: 6
Study: 1016774

Group type: EXPERIMENTAL
Intervention: Hypercapnic conditions (4% CO2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 14
Study: 31841542

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification protocol (directing attention away from energy drink cues in Exp.1 and joystick push away in Exp.2)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification protocol
Number of subjects: 226
Study: 28959907

Group type: EXPERIMENTAL
Intervention: SRP + nDOX
Number of subjects: 45

Group type: COMPARATOR
Intervention: SRP + DOX
Number of subjects: 45

Group type: COMPARATOR
Intervention: SRP + placeboCH
Number of subjects: 45
Study: 26897438

Group type: EXPERIMENTAL
Intervention: Body movement group (Group M) with 6% sevoflurane induction and initial maintenance concentration of 3%.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Central pupils group (Group C) with 6% sevoflurane induction and initial maintenance concentration of 3%.
Number of subjects: 58
Study: 25012408

Group type: EXPERIMENTAL
Intervention: Collaborative care programme
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 338
Study: 22990343

Group type: EXPERIMENTAL
Intervention: Pressure Ulcer Prevention Program (PUPP)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (standard practice following AHRQ guidelines)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: PUPP
Number of subjects: 133
Study: 20440479

Group type: EXPERIMENTAL
Intervention: Eyeball/estimated POP-Q examination
Number of subjects: 50

Group type: COMPARATOR
Intervention: Measured POP-Q examination
Number of subjects: 50
Study: 17375008

Group type: EXPERIMENTAL
Intervention: 595 nm pulse dye laser therapy (PDL) with settings: spot diameter 5 mm, pulse duration 0.45 ms, fluence 9 J/cm2, 5 passes at 1 Hz, with cryogen spray cooling.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 595 nm pulse dye laser therapy (PDL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (cooling pulses only)
Number of subjects: 35
Study: 15723981

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 6632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6632
Study: 12487007

Group type: EXPERIMENTAL
Intervention: IFT 1 (10-20 Hz)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IFT 2 (80-100 Hz)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (identical procedure without current)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study: 9579389

Group type: EXPERIMENTAL
Intervention: Ascitic fluid from patients with cirrhosis
Number of subjects: 27

Group type: COMPARATOR
Intervention: Peritoneal dialysis effluent (PDE) from CAPD patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Peritoneal/plasma ratios of HA in cirrhotic patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlation of ascitic HA levels with interleukin‐1beta, interleukin‐6, and transforming growth factor‐beta
Number of subjects: 27
Study: 7650078

Group type: EXPERIMENTAL
Intervention: iohexol 300 mgI/ml (100 ml, n = 17)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: ioversol 320 mgI/ml (100 ml, n = 13)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: iopromide 300 mgI/ml (75 ml, n = 12)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: iopentol 300 mgI/ml (100 ml, n = 11)
Number of subjects: 53
Study: 2711141

Group type: EXPERIMENTAL
Intervention: Intervention group (673 men) received advice to reduce risk during two home visits and quarterly newsletters.
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Control group (number not specified)
Number of subjects: 1373
Study: 342692

Group type: EXPERIMENTAL
Intervention: L-histidine 4.5 g daily for 30 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31839621

Group type: EXPERIMENTAL
Intervention: GD-DAPT
Number of subjects: 5131

Group type: EXPERIMENTAL
Intervention: GD-DAPT (in ACS patients)
Number of subjects: 5131
Study: 31419622

Group type: EXPERIMENTAL
Intervention: Multi-component nurse-led intervention including nurse-led care coordination, nurse-managed medication protocols and adherence support, home BP monitoring, and electronic health records support tools.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care with generic prevention education (control group).
Number of subjects: 300
Study: 28095832

Group type: EXPERIMENTAL
Intervention: Motion-sensor biofeedback treatment in addition to guidelines-based care
Number of subjects: 83

Group type: COMPARATOR
Intervention: Guidelines-based care alone
Number of subjects: 83
Study: 26383176

Group type: EXPERIMENTAL
Intervention: Clinical aromatherapy 3 times a week for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control therapy 3 times a week for 4 weeks
Number of subjects: 14
Study: 23149074

Group type: EXPERIMENTAL
Intervention: Moderate gazpacho consumption
Number of subjects: 3995

Group type: EXPERIMENTAL
Intervention: High gazpacho consumption
Number of subjects: 3995

Group type: COMPARATOR
Intervention: Gazpacho consumption (250 g/week increase)
Number of subjects: 3995

Group type: COMPARATOR
Intervention: High gazpacho consumption groups
Number of subjects: 3995
Study: 21623468

Group type: EXPERIMENTAL
Intervention: Whey protein enriched dairy product with high leucine content (Test)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Regular dairy product (Control)
Number of subjects: 47
Study: 18470670

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 142

Group type: COMPARATOR
Intervention: No additive treatment (Control)
Number of subjects: 142
Study: 16873795

Group type: EXPERIMENTAL
Intervention: Diabetes risk score based on age, BMI, waist circumference, hypertension, and family history of diabetes
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Diabetes risk score with added impaired fasting glucose or impaired glucose tolerance
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Diabetes risk score with added low HDL cholesterol and/or high triglycerides
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 2677
Study: 14592408

Group type: EXPERIMENTAL
Intervention: Serotonin transporter (5‐HTT) gene promoter polymorphism
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 78
Study: 10719612

Group type: EXPERIMENTAL
Intervention: 360 mg AS 195
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 720 mg AS 195
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 360 mg AS 195 and 720 mg AS 195
Number of subjects: 260
Study: 8923635

Group type: EXPERIMENTAL
Intervention: Implanted bone growth stimulation
Number of subjects: 94

Group type: COMPARATOR
Intervention: No stimulation (Control)
Number of subjects: 94
Study: 7897675

Group type: EXPERIMENTAL
Intervention: Sexually active women
Number of subjects: 142

Group type: COMPARATOR
Intervention: Sexually abstinent women
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both groups (active and abstinent)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Younger elderly (age 69 or below)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Older elderly (age 70 or above)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Sexually active and abstinent women
Number of subjects: 142
Study: 3677541

Group type: EXPERIMENTAL
Intervention: Nicainoprol (100 mg intravenous infusion)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicainoprol (200 mg oral dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicainoprol (both doses)
Number of subjects: 8
Study: 31397211

Group type: EXPERIMENTAL
Intervention: FNMES (fatiguing neuromuscular electrical stimulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CTRL (unfatigued state)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison between CTRL and FNMES
Number of subjects: 12
Study: 29683337

Group type: EXPERIMENTAL
Intervention: Foot mobilization and exercise combined with a toe separator
Number of subjects: 56

Group type: COMPARATOR
Intervention: No intervention (waiting list)
Number of subjects: 56
Study: 24903387

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin inhibitors
Number of subjects: 853
Study: 21927036

Group type: EXPERIMENTAL
Intervention: Oxygen+intermittent non-invasive ventilation (NIV)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Oxygen supply only
Number of subjects: 526
Study: 20402569

Group type: EXPERIMENTAL
Intervention: L-tryptophan supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18505128

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 219

Group type: COMPARATOR
Intervention: Repaglinide
Number of subjects: 219
Study: 15606381

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 12618257

Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: No lorazepam (observational group)
Number of subjects: 104
Study: 10319775

Group type: EXPERIMENTAL
Intervention: Low-dose sevoflurane (end-tidal concentration, 0.25%)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no sevoflurane)
Number of subjects: 18
Study: 7588486

Group type: EXPERIMENTAL
Intervention: DMSA (meso-2,3-dimercaptosuccinic acid)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cholestyramine administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Neomycin administration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lead exposure
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: DMSA metabolite
Number of subjects: 6
Study: 2277372

Group type: EXPERIMENTAL
Intervention: 80‐mg terconazole suppositories for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miconazole nitrate suppositories for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo suppositories for 7 days
Number of subjects: 0
Study: 6985830

Group type: EXPERIMENTAL
Intervention: Weekly cyclophosphamide, cytosine arabinoside, and methotrexate (CAM)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Twice daily cytosine arabinoside and thioguanine (AT)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Overall response rate for both treatments
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Overall response rate for patients surviving three weeks or longer
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Median survival for all evaluable patients
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Median survival for patients who achieved CR
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Median survival for patients who did not achieve CR
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Toxicity comparison
Number of subjects: 151
Study: 31981557

Group type: EXPERIMENTAL
Intervention: Facility-based HIV self-testing (Oraquick HIV self-test, group demonstration and distribution, and private spaces for interpretation and counselling)
Number of subjects: 5885

Group type: COMPARATOR
Intervention: Standard provider-initiated testing and counselling (no intervention)
Number of subjects: 5885

Group type: COMPARATOR
Intervention: Optimised provider-initiated testing and counselling (with additional provider training and morning HIV testing)
Number of subjects: 5885

Group type: EXPERIMENTAL
Intervention: Facility-based HIV self-testing
Number of subjects: 5885

Group type: COMPARATOR
Intervention: Standard provider-initiated testing and counselling and optimised provider-initiated testing and counselling
Number of subjects: 5885
Study: 30686693

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Integra
Number of subjects: 36
Study: 28474968

Group type: EXPERIMENTAL
Intervention: PRGF + GTR
Number of subjects: 14

Group type: COMPARATOR
Intervention: GTR alone
Number of subjects: 14
Study: 26860024

Group type: EXPERIMENTAL
Intervention: Transoesophageal Doppler (TED) guidance for fluid management
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard clinical monitoring parameters
Number of subjects: 40
Study: 23396176

Group type: EXPERIMENTAL
Intervention: Ondansetron 16mg/day
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 20570081

Group type: EXPERIMENTAL
Intervention: Online video-based education
Number of subjects: 94

Group type: COMPARATOR
Intervention: Pamphlet-based education
Number of subjects: 94
Study: 19584761

Group type: EXPERIMENTAL
Intervention: Automated voice response (AVR) system
Number of subjects: 386

Group type: COMPARATOR
Intervention: Nurse-assisted symptom management
Number of subjects: 386
Study: 16838599

Group type: EXPERIMENTAL
Intervention: Prevention of cardiovascular morbidity and mortality in patients with hypertension
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Overall conclusions for men and women in myocardial infarction studies
Number of subjects: 139
Study: 15280524

Group type: EXPERIMENTAL
Intervention: High-flux polysulphone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-flux modified cellulose
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (low-flux polysulphone)
Number of subjects: 36
Study: 11758850

Group type: EXPERIMENTAL
Intervention: UFT 300 mg/m2/day with oral Folinic acid 7.5 mg/dose for 21 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 28